Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jorge Castillo, M.D.

Title
Institution
Department
Address
Profile Picture

Biography
awards and honors
2012 - 2012
Best Lymphoma Abstract, Lymphoma & Myeloma 2012
1996 - 1996
Top 10%, UAM-X Medical School

Overview
overview
Dr. Castillo was born in the northern coast of Peru. He received his medical degree in Mexico City, and completed his Hematology and Oncology training at Brown University. After 5 years as an Assistant Professor of Medicine at Brown University, Dr. Castillo was appointed Assistant Professor at Harvard Medical School. His clinical practice and research interests at the Dana-Farber Cancer Institute focus on patients with Waldenstrom Macroglobulinemia. He is currently the principal investigator in a series of clinical trials evaluating highly effective non-chemotherapeutic approaches.

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sarosiek S, Treon SP, Castillo JJ. How to Sequence Therapies in Waldenström Macroglobulinemia. Curr Treat Options Oncol. 2021 Aug 23; 22(10):92. PMID: 34426943.
    Citations:    Fields:    
  2. Castillo JJ, LaMacchia J, Flynn CA, Sarosiek S, Pozdnyakova O, Treon SP. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 Aug 06. PMID: 34355802.
    Citations:    Fields:    
  3. Castillo JJ, Lamacchia J, Silver J, Flynn CA, Sarosiek S. Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma. Am J Hematol. 2021 Oct 01; 96(10):E390-E392. PMID: 34260089.
    Citations: 1     Fields:    
  4. Jalink M, Berentsen S, Castillo JJ, Treon SP, Cruijsen M, Fattizzo B, Cassin R, Fotiou D, Kastritis E, De Haas M, Oosten LEM, Frederiksen H, Patriarca A, D'Sa S, Vos JMI. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021 07 22. PMID: 34293088.
    Citations:    Fields:    
  5. Treon SP, Meid K, Hunter ZR, Flynn CA, Sarosiek SR, Leventoff CR, White TP, Cao Y, Roccaro AM, Sacco A, Demos MG, Guerrera ML, Kofides A, Liu X, Xu L, Patterson CJ, Munshi M, Tsakmaklis N, Yang G, Ghobrial IM, Branagan AR, Castillo JJ. Phase I study of Ibrutinib and the CXCR4 antagonist Ulocuplumab in CXCR4 mutated Waldenstrom Macroglobulinemia. Blood. 2021 07 21. PMID: 34289017.
    Citations:    Fields:    
  6. Kofides A, Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Munshi M, Liu X, Guerrera ML, Leventoff CR, White TP, Flynn CA, Meid K, Patterson CJ, Yang G, Branagan AR, Sarosiek S, Castillo JJ, Treon SP, Gustine JN. Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. Hemasphere. 2021 Aug; 5(8):e624. PMID: 34291197.
    Citations:    
  7. Malpica L, Enriquez DJ, Castro DA, Peña C, Idrobo H, Fiad L, Prates M, Otero V, Biglione M, Altamirano M, Sandival-Ampuero G, Aviles-Perez U, Meza K, Aguirre-Martinez L, Cristaldo N, Maradei JL, Guanchiale L, Soto P, Viñuela JL, Cabrera ME, Paredes SR, Riva E, Di Stefano M, Noboa A, Choque JA, Candelaria M, Von Glasenapp A, Valvert F, Torres-Viera MA, Castillo JJ, Ramos JC, Villela L, Beltran BE. Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Glob Oncol. 2021 07; 7:1151-1166. PMID: 34270330.
    Citations:    Translation:Humans
  8. Gustine JN, Sarosiek S, Flynn CA, Meid K, Leventoff C, White T, Guerrera ML, Xu L, Kofides A, Tsakmaklis N, Munshi M, Demos M, Patterson CJ, Liu X, Yang G, Hunter ZR, Branagan AR, Treon SP, Castillo JJ. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2021 Jun 24. PMID: 34162182.
    Citations:    Fields:    
  9. Castillo JJ, Beltran BE, Malpica L, Marques-Piubelli ML, Miranda RN. Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK?+?LBCL): a systematic review of clinicopathological features and management. Leuk Lymphoma. 2021 Jun 21; 1-9. PMID: 34151703.
    Citations:    Fields:    
  10. Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP. The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 06 16. PMID: 34132782.
    Citations:    Fields:    
  11. Martz CA, Jarbeau JF, Castillo JJ, Fisher DC, Nohria A. Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma. JACC CardioOncol. 2021 Jun; 3(2):326-329. PMID: 34396343.
    Citations:    
  12. Mozessohn L, Zhang L, Odejide OO, Chen R, Buckstein R, Soiffer RJ, Castillo JJ, Driver JA, Abel GA. Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leuk Lymphoma. 2021 Jun 11; 1-8. PMID: 34114930.
    Citations:    Fields:    
  13. Demos MG, Hunter ZR, Xu L, Tsakmaklis N, Kofides A, Munshi M, Liu X, Guerrera ML, Leventoff CR, White TP, Flynn CA, Meid K, Patterson CJ, Yang G, Branagan AR, Sarosiek S, Castillo JJ, Treon SP, Gustine JN. Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253. PMID: 33819355.
    Citations: 1     Fields:    Translation:Humans
  14. Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021 07 01; 96(7):846-853. PMID: 33709474.
    Citations: 1     Fields:    Translation:HumansAnimals
  15. Gustine JN, Xu L, Yang G, Liu X, Kofides A, Tsakmaklis N, Munshi M, Demos M, Guerrera ML, Meid K, Patterson CJ, Sarosiek S, Branagan AR, Hunter ZR, Castillo JJ, Treon SP. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. Br J Haematol. 2021 Aug; 194(4):730-733. PMID: 33713429.
    Citations: 1     Fields:    
  16. Sarosiek S, Treon SP, Castillo JJ. Reducing treatment toxicity in Waldenström macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676. PMID: 33645373.
    Citations:    Fields:    Translation:Humans
  17. Branagan AR, Lei M, Treon SP, Castillo JJ. Clinical application of genomics in Waldenström macroglobulinemia. Leuk Lymphoma. 2021 08; 62(8):1805-1815. PMID: 33569985.
    Citations:    Fields:    Translation:Humans
  18. Castro D, Beltrán B, Quiñones MDP, Pachas C, Huerta Y, Lalupu K, Mendoza R, Castillo JJ. Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leuk Res. 2021 03; 102:106513. PMID: 33561632.
    Citations:    Fields:    Translation:Humans
  19. Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, D'Sa S, Owen RG, Cull G, Mulligan S, Czyz J, Castillo JJ, Motta M, Siddiqi T, Gironella Mesa M, Granell Gorrochategui M, Talaulikar D, Zinzani PL, Askari E, Grosicki S, Oriol A, Rule S, Kloczko J, Tedeschi A, Buske C, Leblond V, Trotman J, Chan WY, Michel J, Schneider J, Tan Z, Cohen A, Huang J, Tam CS. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020 12 08; 4(23):6009-6018. PMID: 33284944.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  20. Castillo JJ, Treon SP. Management of Waldenström macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379. PMID: 33275726.
    Citations: 2     Fields:    Translation:Humans
  21. Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 12 02; 18(12):1685-1717. PMID: 33285522.
    Citations: 8     Fields:    
  22. Castillo JJ, Abeykoon JP, Gustine JN, Zanwar S, Mein K, Flynn CA, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, King R, Yang G, Hunter ZR, Advani RH, Palomba ML, Ansell SM, Gertz MA, Kapoor P, Treon SP. Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 02; 192(3):542-550. PMID: 33207010.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  23. Durot E, Kanagaratnam L, Zanwar S, Kastritis E, D'Sa S, Garcia-Sanz R, Tomowiak C, Hivert B, Toussaint E, Protin C, Abeykoon JP, Guerrero-Garcia T, Itchaki G, Vos JM, Michallet AS, Godet S, Dupuis J, Leprêtre S, Bomsztyk J, Morel P, Leblond V, Treon SP, Dimopoulos MA, Kapoor P, Delmer A, Castillo JJ. A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica. 2020 11 12; Online ahead of print. PMID: 33179472.
    Citations:    Fields:    Translation:Humans
  24. Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Talaulikar D, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837. PMID: 33091356.
    Citations: 4     Fields:    Translation:Humans
  25. Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020 10 29; 136(18):2038-2050. PMID: 32731259.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  26. Castillo JJ, Libby EN, Ansell SM, Palomba ML, Meid K, Flynn CA, Leventoff C, Hergott CB, Sewastianik T, Morgan EA, Carrasco R, Fromm JR, Yang G, Hunter Z, Treon SP. Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Adv. 2020 10 27; 4(20):5089-5092. PMID: 33085756.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  27. Jiménez C, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chan GG, Guerrera ML, Chen JG, Liu X, Munshi M, Patterson CJ, Yang G, Castillo JJ, Treon SP, Hunter ZR. Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia. Blood Adv. 2020 09 22; 4(18):4550-4553. PMID: 32956451.
    Citations: 1     Fields:    Translation:Humans
  28. Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, Patterson CJ, Hunter ZR, Branagan AR, Laubach JP, Ghobrial IM, Palomba ML, Advani R, Castillo JJ. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 Feb 20; 39(6):565-575. PMID: 32931398.
    Citations: 3     Fields:    
  29. Castillo JJ, Meid K, Flynn CA, Chen J, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Yang G, Hunter Z, Treon SP. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959. PMID: 32822482.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  30. Talaulikar D, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E, Castillo JJ. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Aug; 4(4):e433. PMID: 32803133.
    Citations: 2     
  31. Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, Krawczyk K, Stork M, Pour L, Usnarska-Zubkiewicz L, Potoczek S, Hus I, Davila Valls J, Hari P, Chhabra S, Gentile M, Mikala G, Varga G, Chim CS, Fiala M, Vij R, Schutz N, Rodzaj M, Porowska A, Vesole DH, Druzd-Sitek A, Walewski J, Nooka AK. Primary refractory multiple myeloma: a real-world experience with 85 cases. Leuk Lymphoma. 2020 12; 61(12):2868-2875. PMID: 32623944.
    Citations:    Fields:    Translation:Humans
  32. Aguilar C, Laberiano C, Beltran B, Diaz C, Taype-Rondan A, Castillo JJ. Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. Leuk Lymphoma. 2020 09; 61(9):2093-2102. PMID: 32449626.
    Citations: 1     Fields:    Translation:HumansCells
  33. Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. Hemasphere. 2020 Jun; 4(3):e363. PMID: 32647793.
    Citations:    
  34. Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, Meid K, Yang G. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915. PMID: 32302379.
    Citations: 92     Fields:    Translation:HumansCellsPHPublic Health
  35. Beltrán BE, Villela L, Torres MA, Otero V, Fiad L, Peña C, Cabrera ME, León P, Idrobo H, Castro DA, Paredes S, Perdomo I, Abello V, Rojas C, Ramirez-Ibargüen A, Candelaria M, Pérez-Jacobo F, Montaño-Figueroa E, Best C, Goméz-De Leon A, Gómez-Almaguer D, Ruiz-Argüelles G, Hernández-Hernández J, Malpica L, Sotomayor EM, Castillo JJ. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):637-646. PMID: 32513598.
    Citations:    Fields:    Translation:HumansCells
  36. Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grzasko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Valls JD, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski L, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Mazur P, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozlowska I, Goldberg SL, Czepiel J, Dlugosz-Danecka M, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Vesole DH. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leuk Lymphoma. 2020 08; 61(8):1885-1893. PMID: 32306794.
    Citations: 1     Fields:    Translation:Humans
  37. Beltran BE, Castro D, Paredes S, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 04; 95(4):435-445. PMID: 32072672.
    Citations: 6     Fields:    Translation:HumansCells
  38. Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grzasko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Davila Valls J, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski L, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozlowska I, Goldberg SL, Czepiel J, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Dlugosz-Danecka M, Grosicki S, Vesole DH. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol. 2020 05; 95(5):503-509. PMID: 32072687.
    Citations: 2     Fields:    Translation:Humans
  39. Jiménez C, Chan GG, Xu L, Tsakmaklis N, Kofides A, Demos MG, Chen J, Liu X, Munshi M, Yang G, Castillo JJ, Wiestner A, García-Sanz R, Treon SP, Hunter ZR. Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170. PMID: 32103491.
    Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
  40. Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, Demos M, Gustine J, Chan G, Munshi M, Tsakmaklis N, Chen JG, Kofides A, Sklavenitis-Pistofidis R, Bustoros M, Keezer A, Meid K, Patterson CJ, Sacco A, Roccaro A, Branagan AR, Yang G, Ghobrial IM, Castillo JJ. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 04 10; 38(11):1198-1208. PMID: 32083995.
    Citations: 11     Fields:    Translation:Humans
  41. Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Jimenez C, Chan GG, Hunter ZR, Palomba ML, Argyropoulos KV, Meid K, Keezer A, Gustine J, Dubeau T, Castillo JJ, Patterson CJ, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12. PMID: 32005797.
    Citations: 9     Fields:    Translation:HumansCells
  42. Castillo JJ, Itchaki G, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Leuk Lymphoma. 2020 06; 61(6):1388-1394. PMID: 31992103.
    Citations: 1     Fields:    Translation:Humans
  43. Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 04; 95(4):E95-E98. PMID: 31943341.
    Citations: 2     Fields:    Translation:Humans
  44. Liu X, Chen JG, Munshi M, Hunter ZR, Xu L, Kofides A, Tsakmaklis N, Demos MG, Guerrera ML, Chan GG, Jimenez C, Patterson CJ, Meid K, Keezer A, Castillo JJ, Treon SP, Yang G. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Adv. 2020 01 14; 4(1):141-153. PMID: 31935288.
    Citations: 2     Fields:    Translation:HumansCells
  45. Castillo JJ, Gustine JN, Keezer A, Meid K, Flynn CA, Dubeau TE, Chan G, Chen J, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2020 04; 95(4):372-378. PMID: 31868242.
    Citations:    Fields:    Translation:Humans
  46. Olszewski AJ, Butera JN, Reagan JL, Castillo JJ. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2020 04; 95(4):354-361. PMID: 31849108.
    Citations: 3     Fields:    Translation:Humans
  47. Castillo JJ. Evolution of Therapy for Relapsed/Refractory Multiple Myeloma. J Natl Compr Canc Netw. 2019 11; 17(11.5):1433-1436. PMID: 31766022.
    Citations: 1     Fields:    Translation:Humans
  48. Gustine JN, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Keezer A, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ. CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. Blood Adv. 2019 10 08; 3(19):2800-2803. PMID: 31570491.
    Citations: 10     Fields:    Translation:Humans
  49. Castillo JJ, Treon SP. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562. PMID: 31591468.
    Citations: 3     Fields:    Translation:Humans
  50. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. J Natl Compr Canc Netw. 2019 10 01; 17(10):1154-1165. PMID: 31590151.
    Citations: 18     Fields:    Translation:Humans
  51. Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285. PMID: 31430829.
    Citations: 3     Fields:    Translation:Humans
  52. Bustoros M, Sklavenitis-Pistofidis R, Castillo JJ, Treon SP, Ghobrial IM. Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702. PMID: 31424980.
    Citations:    Fields:    Translation:Humans
  53. Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, Seny GM, Glickman S, Jayabalan DS, Niesvizky R, Gozzetti A, Wisniewska-Piaty K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Hus I, Guzicka R, Radocha J, Milunovic V, Davila J, Gentile M, Castillo JJ, Jurczyszyn A. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol. 2019 10; 94(10):1132-1140. PMID: 31334859.
    Citations: 2     Fields:    Translation:HumansCells
  54. Castillo JJ. HOLA! from Latin America to the myeloma world. Br J Haematol. 2020 02; 188(3):349-350. PMID: 31378927.
    Citations: 1     Fields:    Translation:Humans
  55. Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881. PMID: 31343930.
    Citations: 4     Fields:    Translation:Humans
  56. Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE, Liu X, Demos MG, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Yang G, Hunter ZR, Treon SP. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363. PMID: 31267520.
    Citations: 16     Fields:    Translation:Humans
  57. Beltran BE, Paredes S, Castro D, Cotrina E, Sotomayor EM, Castillo JJ. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):e551-e557. PMID: 31320254.
    Citations: 1     Fields:    Translation:Humans
  58. Juárez-Salcedo LM, Castillo JJ. Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematol Oncol Clin North Am. 2019 08; 33(4):639-656. PMID: 31229160.
    Citations: 1     Fields:    Translation:Humans
  59. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411. PMID: 30990729.
    Citations: 11     Fields:    Translation:Humans
  60. Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305. PMID: 30523119.
    Citations: 7     Fields:    Translation:Humans
  61. Cheng MP, Kusztos AE, Gustine JN, Dryden-Peterson SL, Dubeau TE, Woolley AE, Hammond SP, Baden LR, Treon SP, Castillo JJ, Issa NC. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790. PMID: 30460682.
    Citations: 3     Fields:    Translation:HumansAnimals
  62. Barth P, Castillo JJ, Olszewski AJ. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Cancer. 2019 02 15; 125(4):550-558. PMID: 30452087.
    Citations: 1     Fields:    Translation:Humans
  63. Olszewski AJ, Castillo JJ. Ibrutinib and Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 11 15; 379(20):1973-4. PMID: 30439672.
    Citations: 1     Fields:    Translation:Humans
  64. Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946. PMID: 30401751.
    Citations: 14     Fields:    Translation:HumansCells
  65. Babwah A, Gustine J, Meid K, Dubeau T, Xu L, Yang G, Hunter ZR, Treon SP, Castillo JJ. Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802. PMID: 30407630.
    Citations: 1     Fields:    Translation:Humans
  66. Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612. PMID: 30366921.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  67. Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M. Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018; 13(10):e0204589. PMID: 30286096.
    Citations: 5     Fields:    Translation:HumansCells
  68. Castillo JJ, Kastritis E, Treon SP. Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematol Oncol Clin North Am. 2018 10; 32(5):xiii-xiv. PMID: 30190026.
    Citations:    Fields:    Translation:Humans
  69. Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ, Xu L. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245. PMID: 30183082.
    Citations: 6     Fields:    Translation:Humans
  70. Jurczyszyn A, Castillo JJ, Vesole DH, Liu J, Avivi I, Waszczuk-Gajda A, Lech-Maranda E, Gentile M, Mikala G, Guerrero-Garcia T, Suska A, Gertz MA. Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. Am J Hematol. 2018 09; 93(9):E238-E241. PMID: 29989240.
    Citations:    Fields:    Translation:Humans
  71. Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, Demos M, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Chan G, Dubeau T, Raje N, Yee A, O'Donnell E, Hunter ZR, Castillo JJ. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761. PMID: 30044692.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  72. Treon SP, Xu L, Liu X, Hunter ZR, Yang G, Castillo JJ. Genomic Landscape of Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):745-752. PMID: 30190014.
    Citations: 1     Fields:    Translation:HumansCells
  73. Castillo JJ, Treon SP. Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):811-820. PMID: 30190019.
    Citations: 2     Fields:    Translation:Humans
  74. Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wisniewska-Piaty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Razny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. Leuk Lymphoma. 2019 02; 60(2):471-476. PMID: 30033832.
    Citations: 3     Fields:    Translation:Humans
  75. Dominguez A, Kastritis E, Castillo JJ. Monoclonal Antibodies for Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 Oct; 32(5):841-852. PMID: 30190022.
    Citations:    Fields:    Translation:Humans
  76. Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grzasko N, Milunovic V, Hus I, Madry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Debski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charlinski G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 01; 60(1):118-123. PMID: 29965787.
    Citations: 3     Fields:    Translation:Humans
  77. Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 07; 93(7):953-962. PMID: 29984868.
    Citations: 12     Fields:    Translation:HumansCells
  78. Treon SP, Castillo JJ. The real world of Waldenström's macroglobulinaemia. Lancet Haematol. 2018 07; 5(7):e275-e276. PMID: 29958567.
    Citations: 1     Fields:    Translation:Humans
  79. Castillo JJ. Viral lymphomagenesis: beyond the usual suspects. Br J Haematol. 2018 09; 182(5):617-618. PMID: 29808932.
    Citations:    Fields:    Translation:HumansCells
  80. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Xu L, Yang G, Hunter ZR, Advani R, Palomba L, Treon SP. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468. PMID: 29773590.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  81. Castillo JJ, Dubeau T, Kofides A, Demos MG, Tsakmaklis N, Xu L, Hunter ZR, Treon SP. Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia. Am J Hematol. 2018 May 14. PMID: 29756293.
    Citations:    Fields:    
  82. Castillo JJ, Gustine JN, Treon SP. Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. JAMA Oncol. 2018 05 01; 4(5):744-745. PMID: 29392274.
    Citations:    Fields:    Translation:Humans
  83. Singh A, Geller HI, Alexander KM, Padera RF, Mitchell RN, Dorbala S, Castillo JJ, Falk RH. True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis. Haematologica. 2018 08; 103(8):e374-e376. PMID: 29674499.
    Citations: 1     Fields:    Translation:Humans
  84. Castillo JJ, Meid K, Gustine JN, Dubeau T, Severns P, Hunter ZR, Yang G, Xu L, Treon SP. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. Clin Cancer Res. 2018 07 15; 24(14):3247-3252. PMID: 29661775.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  85. Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR. MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica. 2018 09; 103(9):e408-e411. PMID: 29599202.
    Citations: 6     Fields:    Translation:Humans
  86. Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Xu L, Yang G, Hunter ZR, Treon SP. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol. 2019 03; 184(6):1011-1014. PMID: 29532913.
    Citations: 4     Fields:    Translation:Humans
  87. Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019 02; 184(4):679-682. PMID: 29527667.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  88. Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid K, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018 05 03; 131(18):2047-2059. PMID: 29496671.
    Citations: 20     Fields:    Translation:HumansCells
  89. Beltran BE, Castro D, De La Cruz-Vargas JA, Cotrina E, Gallo A, Sotomayor EM, Castillo JJ. The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. Br J Haematol. 2019 02; 184(4):650-653. PMID: 29479670.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  90. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, Yang G, Hunter ZR, Treon SP. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018 04; 181(1):77-85. PMID: 29468652.
    Citations: 6     Fields:    Translation:Humans
  91. Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Treon SP. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310. PMID: 29472352.
    Citations: 9     Fields:    Translation:Humans
  92. Beltrán BE, Paredes S, Cotrina E, Sotomayor EM, Castillo JJ. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. Leuk Res. 2018 04; 67:82-85. PMID: 29477024.
    Citations: 1     Fields:    Translation:HumansCells
  93. Gustine JN, Meid K, Dubeau T, Severns P, Hunter ZR, Guang Y, Xu L, Treon SP, Castillo JJ. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517. PMID: 29280186.
    Citations: 11     Fields:    Translation:Humans
  94. Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grzasko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charlinski G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopinska-Posluszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018 03; 180(6):831-839. PMID: 29315478.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  95. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw. 2018 01; 16(1):11-20. PMID: 29295877.
    Citations: 27     Fields:    Translation:Humans
  96. Castillo JJ, Gustine JN, Meid K, Xu L, Hunter ZR, Treon SP. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 03; 93(3):E69-E71. PMID: 29218718.
    Citations:    Fields:    Translation:Humans
  97. Castillo JJ, Treon SP. Toward personalized treatment in Waldenström macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370. PMID: 29222280.
    Citations: 1     Fields:    Translation:Humans
  98. Treon SP, Castillo JJ. What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Adv. 2017 Nov 28; 1(25):2486-2490. PMID: 29296899.
    Citations: 1     Fields:    
  99. Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, Meid K, Guerrera ML, Munshi M, Chan G, Chen J, Kofides A, Patterson CJ, Yang G, Liu X, Severns P, Dubeau T, Hunter ZR, Castillo JJ. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018 02; 180(3):374-380. PMID: 29181840.
    Citations: 19     Fields:    Translation:Humans
  100. Beltran BE, Quiñones P, Sanchez G, Paredes A, Moises C, Cotrina E, Torres-Cabala CA, Miranda RN, Castillo JJ. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? Leuk Lymphoma. 2018 07; 59(7):1753-1755. PMID: 29081245.
    Citations: 2     Fields:    Translation:Humans
  101. Olszewski AJ, Reagan JL, Castillo JJ. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. Am J Hematol. 2018 01; 93(1):E1-E3. PMID: 28960532.
    Citations: 5     Fields:    Translation:Humans
  102. Qunaj L, Castillo JJ, Olszewski AJ. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018 06; 59(6):1375-1383. PMID: 29019447.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  103. Guerrero-Garcia TA, Mogollon RJ, Castillo JJ. Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat dis